Evidence mapPaperPMID 42358646Full record

ReviewJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques2026

Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.

Gatadi Srikanth, Niggula Praveen Kumar, Bhima Sridevi, Padma Bhavani Borra, Parul Thapar, Aabid Wani

Abstract readReview
In one paragraph

Review in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gatadi SrikanthGITAM School of Pharmacy, GITAM (Deemed to be University), Hyderabad, India.
Niggula Praveen KumarDepartment of Pharmaceutical Chemistry, Bharat Institute of Technology, Hyderabad, India.
Bhima SrideviDepartment of Pharmacy, KL College of Pharmacy, Koneru Lakshmaiah Education Foundation (Deemed to be University), Vaddeswaram, Guntur, India.
Padma Bhavani BorraDepartment of Pharmaceutical Chemistry, Vision College of Pharmaceutical Sciences and Research, Hyderabad, Telangana, India.
Parul ThaparDepartment of Food and Nutrition, Swami Vivekananda University, Barrackpore, West Bengal, India.
Aabid WaniGITAM School of Pharmacy, GITAM (Deemed to be University), Hyderabad, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is a globally accelerating issue threatening the efficacy of existing treatments. Repurposing approved drugs for the development of new antimicrobial agents reduces the development cost and risk. The clinical potential of repurposed medications for AMR is essential to implement coordinated strategies that encompass scientific validation and supportive regulatory frameworks. Repurposing serves as a strong method to prolong the effectiveness of current antimicrobial classes and to fill significant voids in the global AMR pipeline. The present review summarizes current trends in repurposing strategies against AMR, utilization of non-antibiotic drugs with antibacterial activity, agents that potentiate conventional antibiotics through membrane disruption or efflux pump inhibition, and host-directed therapies that modulate immune responses and combination therapies. We also highlight advances in systems pharmacology,

Indexed as

Anti-Bacterial AgentsDrug RepositioningDrug Resistance, BacterialAnimalsHumansAnti-Bacterial Agentsadjuvantsantimicrobial resistancecombination therapydrug repurposingpathogens

Identifiers

PMID42358646
PMCPMC13292040

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.